NYSE: MTNB - Matinas BioPharma Holdings, Inc.

半年間の収益性: +229.52%
セクタ: Healthcare

プロモーションスケジュール Matinas BioPharma Holdings, Inc.


会社について

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions.

さらに詳しく
The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

IPO date 2014-08-18
ISIN US5768101058
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.matinasbiopharma.com
Цена ао 0.2857
1日あたりの価格変動: -1.33% (0.525)
週ごとの価格変動: -4.95% (0.545)
月ごとの料金変更: -17.61% (0.6287)
3ヶ月間の価格変動: -85.49% (3.57)
半年間の価格変動: +229.52% (0.1572)
年間の価格変動: +139.81% (0.216)
3年間の価格推移: -50.67% (1.05)
5年間の価格推移: -54.16% (1.13)
10年間の価格推移: 0% (0.518)
年初からの価格変動: -17.61% (0.6287)

過小評価

名前 意味 学年
P/S 43.41 1
P/BV 2.47 6
P/E 0 0
EV/EBITDA -2.03 0
合計: 3.88

効率

名前 意味 学年
ROA, % -34.98 0
ROE, % -119.2 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.1558 10
合計: 9.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 1117.78 10
収益性 Ebitda, % 14.7 3
収益性 EPS, % 4820.54 10
合計: 6



スーパーバイザー 役職 支払い 生年
Mr. Jerome D. Jabbour J.D. Co-Founder, CEO, President & Director 842.38k 1974 (51 年)
Dr. Theresa Matkovits Ph.D. Chief Development Officer 570.08k 1967 (58 年)
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer 621k 1954 (71 年)
Mr. Keith A. Kucinski CPA, M.B.A. Chief Financial Officer 249.05k 1970 (55 年)
Dr. Hui Liu M.B.A., Ph.D. Chief Technology Officer N/A 1968 (57 年)
Mr. Frank Calamusa Executive Director and Head of Manufacturing & Supply Chain N/A
Mr. Thomas J. Hoover M.B.A. Chief Business Officer N/A 1970 (55 年)

住所: United States, Bedminster. NJ, 1545 Route 206 South - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.matinasbiopharma.com